SG11202002214QA - Topical semisolid composition containing an antimicrobial agent and pirfenidone for the treatment of chronic skin damage - Google Patents
Topical semisolid composition containing an antimicrobial agent and pirfenidone for the treatment of chronic skin damageInfo
- Publication number
- SG11202002214QA SG11202002214QA SG11202002214QA SG11202002214QA SG11202002214QA SG 11202002214Q A SG11202002214Q A SG 11202002214QA SG 11202002214Q A SG11202002214Q A SG 11202002214QA SG 11202002214Q A SG11202002214Q A SG 11202002214QA SG 11202002214Q A SG11202002214Q A SG 11202002214QA
- Authority
- SG
- Singapore
- Prior art keywords
- pirfenidone
- treatment
- composition containing
- antimicrobial agent
- skin damage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2017010486A MX366086B (en) | 2017-08-15 | 2017-08-15 | A semi-solid topical composition containing an antimicrobial agent and pirfenidone for the treatment of chronic skin damage. |
PCT/MX2018/000071 WO2019035705A2 (en) | 2017-08-15 | 2018-08-10 | Topical semisolid composition containing an antimicrobial agent and pirfenidone for the treatment of chronic skin damage |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202002214QA true SG11202002214QA (en) | 2020-04-29 |
Family
ID=64605095
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202002214QA SG11202002214QA (en) | 2017-08-15 | 2018-08-10 | Topical semisolid composition containing an antimicrobial agent and pirfenidone for the treatment of chronic skin damage |
Country Status (15)
Country | Link |
---|---|
US (1) | US11576905B2 (en) |
EP (1) | EP3714872A2 (en) |
JP (2) | JP2020531455A (en) |
KR (1) | KR20200091379A (en) |
CN (1) | CN111246840A (en) |
AR (1) | AR112474A1 (en) |
AU (1) | AU2018317188A1 (en) |
BR (1) | BR112020003001A2 (en) |
CA (1) | CA3072855A1 (en) |
EC (1) | ECSP20010477A (en) |
MX (1) | MX366086B (en) |
PH (1) | PH12020500324A1 (en) |
RU (1) | RU2020110783A (en) |
SG (1) | SG11202002214QA (en) |
WO (1) | WO2019035705A2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2007009796A (en) | 2007-08-14 | 2009-02-25 | Cell Therapy And Technology S | Gel containing pirfenidone. |
MX2011007675A (en) | 2011-07-19 | 2012-07-11 | Cell Therapy And Technology S A De C V | Process for manufacturing a pharmaceutical composition in a sustained-release tablet form containing pirfenidone and the application thereof in the regression of chronic renal failure, breast capsular contracture and liver fibrosis in humans. |
MX346763B (en) | 2012-03-28 | 2017-03-31 | Cell Therapy And Tech S A De C V | Semi-solid topical composition which contains pirfenidone and modified diallyl disulphide oxide (m-ddo) for eliminating or preventing acne. |
MX366086B (en) | 2017-08-15 | 2019-06-27 | Cell Therapy And Tech S A De C V | A semi-solid topical composition containing an antimicrobial agent and pirfenidone for the treatment of chronic skin damage. |
RU2753638C2 (en) * | 2020-01-24 | 2021-08-18 | ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НОВАСКИН" (ООО "Новаскин") | Gel composition for skin treatment |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1049411A (en) | 1972-12-18 | 1979-02-27 | Affiliated Medical Research | N-substituted pyridone and general method for preparing pyridones |
US3839346A (en) | 1972-12-18 | 1974-10-01 | Affiliated Med Res | N-substituted pyridone and general method for preparing pyridones |
US4052509A (en) | 1972-12-18 | 1977-10-04 | Affiliated Medical Research, Inc. | Method for reducing serum uric acid levels |
US4042699A (en) | 1972-12-18 | 1977-08-16 | Affiliated Medical Research, Inc. | Method for reducing serum glucose levels |
US4105782A (en) | 1975-03-07 | 1978-08-08 | Yu Ruey J | Treatment of acne and dandruff |
US4376118A (en) | 1980-10-06 | 1983-03-08 | Miles Laboratories, Inc. | Stable nonaqueous solution of tetracycline salt |
US5310562A (en) | 1989-11-22 | 1994-05-10 | Margolin Solomon B | Composition and method for reparation and prevention of fibrotic lesions |
US5009895A (en) | 1990-02-02 | 1991-04-23 | Merck & Co., Inc. | Sustained release with high and low viscosity HPMC |
AU709474B2 (en) | 1995-12-21 | 1999-08-26 | Zoetis Services Llc | Injectable quinolone formulations |
US5958420A (en) | 1997-03-13 | 1999-09-28 | Nortrade Medical, Inc. | Treatment of burns, cuts, and abrasions of the skin |
US6365131B1 (en) | 1997-10-31 | 2002-04-02 | J. B. Chemicals & Pharmaceuticals Ltd. | Pharmaceutical dental formulation for topical application of metronidazole benzoate, chlorhexidine gluconate and local anesthetic |
DE69917248T2 (en) | 1998-03-17 | 2005-05-04 | Margolin, Solomon B., Dallas | TOPICAL ANTISEPTIC COMPOSITIONS AND METHOD |
GB9810949D0 (en) | 1998-05-22 | 1998-07-22 | Hewlett Healthcare Limited | Formulation |
EP1113798B1 (en) * | 1998-09-18 | 2003-01-02 | Mepha AG | Topical formulation of alkyl-, phenyl-pyridone |
US20020028784A1 (en) | 2000-03-10 | 2002-03-07 | Nest Gary Van | Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences |
IN191090B (en) | 2000-08-29 | 2003-09-20 | Ranbanx Lab Ltd | |
JP4077320B2 (en) | 2001-01-29 | 2008-04-16 | 塩野義製薬株式会社 | Pharmaceutical preparation containing 5-methyl-1-phenyl-2- (1H) -pyridone as an active ingredient |
CH696420A5 (en) * | 2002-09-13 | 2007-06-15 | Mepha Ag | New stable formulations of alkyl, phenyl-pyridones for topical use. |
WO2004073713A1 (en) | 2003-02-21 | 2004-09-02 | Shionogi & Co., Ltd. | Pirfenidone gel preparation |
EP1638625A4 (en) | 2003-05-23 | 2009-08-19 | David M Ott | Organosulphur prodrugs for the prevention and treatment of infectious diseases and pathologenic immune system response |
US20080025986A1 (en) | 2003-06-06 | 2008-01-31 | Ozes Osman N | Methods of Treating Tnf-Mediated Disorders |
US7407973B2 (en) | 2003-10-24 | 2008-08-05 | Intermune, Inc. | Use of pirfenidone in therapeutic regimens |
CN100542532C (en) | 2004-05-24 | 2009-09-23 | 上海睿星基因技术有限公司 | The purposes of pirfenidone in the medicine of preparation treatment hepatic injury necrosis and acute lung injury |
US20060051339A1 (en) | 2004-09-08 | 2006-03-09 | Sivak Hannah N | Composition for treatment of oily skin and acne prevention and methods of making and using same |
US20060115503A1 (en) | 2004-11-30 | 2006-06-01 | Goyal Muna C | Composition, system and method for treatment of skin |
WO2006122154A2 (en) | 2005-05-10 | 2006-11-16 | Intermune, Inc. | Pyridone derivatives for modulating stress-activated protein kinase system |
NZ591443A (en) | 2005-09-22 | 2013-04-26 | Intermune Inc | Granule formation of pirfenidone and pharmaceutically acceptable excipients |
EP1973525B1 (en) | 2005-12-05 | 2014-04-30 | RBA Pharma Inc. | Emulsion-containing medical articles |
CN101088557A (en) | 2006-06-12 | 2007-12-19 | 天津市扶素生物技术有限公司 | Medicine composition for preventing and treating HIV infection and its application |
WO2008107873A1 (en) | 2007-03-02 | 2008-09-12 | Yeda Res & Dev | Mercaptopurine derivatives as anticancer agents |
US20080287508A1 (en) | 2007-05-18 | 2008-11-20 | Intermune, Inc. | Altering pharmacokinetics of pirfenidone therapy |
KR101767849B1 (en) | 2007-06-20 | 2017-08-11 | 오스펙스 파마슈티칼스, 인코포레이티드 | Substituted n-aryl pyridinones as fibrotic inhibitors |
MX2007009796A (en) | 2007-08-14 | 2009-02-25 | Cell Therapy And Technology S | Gel containing pirfenidone. |
US20090137354A1 (en) | 2007-11-27 | 2009-05-28 | Shimano Inc. | Bicycle rear derailleur |
JP2011506446A (en) * | 2007-12-11 | 2011-03-03 | コーダ セラピューティクス, インコーポレイテッド | Injured wound healing composition and treatment |
US20100256031A1 (en) | 2008-10-10 | 2010-10-07 | Jeffrey Wu | Shine control cleanser |
US7635707B1 (en) | 2008-11-10 | 2009-12-22 | Intermune, Inc. | Pirfenidone treatment for patients with atypical liver function |
CN101972225A (en) | 2010-10-13 | 2011-02-16 | 北京诚创康韵医药科技有限公司 | Pirfenidone-contained gel composition |
CN101972236A (en) | 2010-10-13 | 2011-02-16 | 北京诚创康韵医药科技有限公司 | Sustained release preparation containing pirfenidone |
HUE058753T2 (en) | 2011-01-31 | 2022-09-28 | Avalyn Pharma Inc | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
CN102670632A (en) * | 2011-03-12 | 2012-09-19 | 赵海静 | Medical application of pirfenidone in inhibition of skin scar formation |
MX2011007675A (en) | 2011-07-19 | 2012-07-11 | Cell Therapy And Technology S A De C V | Process for manufacturing a pharmaceutical composition in a sustained-release tablet form containing pirfenidone and the application thereof in the regression of chronic renal failure, breast capsular contracture and liver fibrosis in humans. |
MX346763B (en) * | 2012-03-28 | 2017-03-31 | Cell Therapy And Tech S A De C V | Semi-solid topical composition which contains pirfenidone and modified diallyl disulphide oxide (m-ddo) for eliminating or preventing acne. |
MX2012003874A (en) | 2012-03-30 | 2012-11-19 | Moleculas Naturales S A De C V | Method for producing a benzalkonium chloride- diallyl disulfide-oxide complex modified for the use thereof as a biocide. |
MX356551B (en) | 2012-08-23 | 2018-06-04 | Grupo Medifarma S A De C V Star | Antiseptic, antiseborrheic, exfoliating composition for getting rid of or preventing acne. |
CA2819967C (en) | 2012-08-31 | 2016-03-22 | Intermune, Inc. | Use of pirfenidone concomitantly with ciprofloxacin |
AR092742A1 (en) | 2012-10-02 | 2015-04-29 | Intermune Inc | ANTIFIBROTIC PYRIDINONES |
US9156896B2 (en) * | 2013-03-15 | 2015-10-13 | Coda Therapeutics, Inc. | Wound healing compositions and treatments |
MX352342B (en) | 2013-07-12 | 2017-11-22 | Moleculas Naturales S A De C V Star | Process for the manufacture of improved benzethonium chloride-diallyl disulphide oxide modified complex, the obtained complex and uses thereof. |
CN103550242B (en) | 2013-11-22 | 2015-07-15 | 四川国康药业有限公司 | Pharmaceutical composition for treating hepatic fibrosis and preparation method thereof |
WO2017104725A1 (en) * | 2015-12-16 | 2017-06-22 | 第一三共株式会社 | Wound treatment agent |
MX364040B (en) | 2016-11-11 | 2019-04-11 | Cell Therapy And Tech S A De C V | Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (nafld/nash). |
MX366086B (en) | 2017-08-15 | 2019-06-27 | Cell Therapy And Tech S A De C V | A semi-solid topical composition containing an antimicrobial agent and pirfenidone for the treatment of chronic skin damage. |
MX368750B (en) | 2018-08-31 | 2019-10-15 | Cell Therapy And Tech S A De C V | Oil based semisolid pharmaceutical compositions containing pirfenidone for application in tissue repair. |
-
2017
- 2017-08-15 MX MX2017010486A patent/MX366086B/en active IP Right Grant
-
2018
- 2018-08-10 SG SG11202002214QA patent/SG11202002214QA/en unknown
- 2018-08-10 EP EP18839550.3A patent/EP3714872A2/en active Pending
- 2018-08-10 US US16/638,621 patent/US11576905B2/en active Active
- 2018-08-10 JP JP2020508593A patent/JP2020531455A/en active Pending
- 2018-08-10 WO PCT/MX2018/000071 patent/WO2019035705A2/en active Search and Examination
- 2018-08-10 BR BR112020003001-5A patent/BR112020003001A2/en not_active IP Right Cessation
- 2018-08-10 CA CA3072855A patent/CA3072855A1/en active Pending
- 2018-08-10 AU AU2018317188A patent/AU2018317188A1/en active Pending
- 2018-08-10 RU RU2020110783A patent/RU2020110783A/en unknown
- 2018-08-10 CN CN201880066604.2A patent/CN111246840A/en active Pending
- 2018-08-10 KR KR1020207007458A patent/KR20200091379A/en not_active Application Discontinuation
- 2018-08-15 AR ARP180102342 patent/AR112474A1/en unknown
-
2020
- 2020-02-12 EC ECSENADI202010477A patent/ECSP20010477A/en unknown
- 2020-02-13 PH PH12020500324A patent/PH12020500324A1/en unknown
-
2023
- 2023-04-13 JP JP2023065867A patent/JP2023080289A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
RU2020110783A (en) | 2021-09-16 |
EP3714872A2 (en) | 2020-09-30 |
AU2018317188A1 (en) | 2020-04-02 |
WO2019035705A3 (en) | 2019-05-09 |
US11576905B2 (en) | 2023-02-14 |
CA3072855A1 (en) | 2019-02-21 |
RU2020110783A3 (en) | 2021-12-08 |
ECSP20010477A (en) | 2020-04-22 |
PH12020500324A1 (en) | 2020-09-28 |
MX2017010486A (en) | 2018-09-21 |
KR20200091379A (en) | 2020-07-30 |
JP2023080289A (en) | 2023-06-08 |
US20200253944A1 (en) | 2020-08-13 |
CN111246840A (en) | 2020-06-05 |
JP2020531455A (en) | 2020-11-05 |
AR112474A1 (en) | 2019-10-30 |
WO2019035705A2 (en) | 2019-02-21 |
BR112020003001A2 (en) | 2020-08-11 |
MX366086B (en) | 2019-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11202002214QA (en) | Topical semisolid composition containing an antimicrobial agent and pirfenidone for the treatment of chronic skin damage | |
EP3684353A4 (en) | Topical formulations of cannabinoids and use thereof in the treatment of pain | |
IL258854A (en) | Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer | |
ZA201902275B (en) | Topical dressing composition for the treatment of damaged skin tissue | |
IL290150A (en) | Compositions and methods for the treatment of chronic pain | |
EP3664812A4 (en) | Topical skin compositions for treating erythema or skin inflammation | |
EP3328864A4 (en) | Therapeutic compounds and compositions for treating social disorders and substance use disorders | |
IL246036A0 (en) | Therapeutic and/or preventive agent comprising 1-indansulfamide derivative for pain | |
IL274631A (en) | Emulsions for the topical treatment of dermal and mucosal infections | |
SG11201705524SA (en) | Compositions and methods for the treatment of inflammation and pain | |
EP3258908A4 (en) | Compositions and methods for treatment of skin infections | |
ZA202000884B (en) | Compositions for treating skin and mucous membrane infections | |
ZA201905343B (en) | Antiseptic composition comprising polyvinylpyrrolidone and unithiol and use of the composition | |
EP3700528A4 (en) | Methods and compositions for maintaining opioid efficacy in the treatment of pain | |
IL272945A (en) | Topical compositions and methods for treatment | |
IL275899A (en) | Cerdulatinib-containing topical skin pharmaceutical compositions and uses thereof | |
EP3150195A4 (en) | Agent for external use on skin and agent for reducing skin irritation | |
PL3773641T3 (en) | Topical pharmaceutical compositions for treating skin conditions | |
EP3573996A4 (en) | Compound with analgesic effect for use in prevention and treatment of pain | |
EP3508202A4 (en) | Therapeutic agent for amyotrophic lateral sclerosis and composition for treatment | |
HK1213196A1 (en) | Agent for reducing skin irritation and cosmetic composition for skin whitening containing the same | |
PL3272344T3 (en) | Synergistic composition comprising propolis and carnosic acid for use in the prevention and treatment of candidiasis | |
PT3177283T (en) | Active compound and related composition for dermatological use in the pharmaceutical or cosmetic field | |
IL280569A (en) | Uvb-induced photodamages: compositions and methods for topical treatment | |
HK1256597A1 (en) | Composition for alleviating skin wrinkles and treating skin damaging inflammatory diseases, containing cellular senescence inhibitor as active ingredient |